REG-Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
Oculis appointed Prof. Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer, joining from Roche where he led Integrative Neuroscience & Medical Practice. He will lead global scientific strategy and advance lead asset Privosegtor through the PIONEER registrational program, including evaluating its potential in acute multiple sclerosis relapses and other neurological indications. Aaron Tansy, M.D., was also appointed VP, Development Franchise Head, Neurology, bringing Phase 1-3 development experience from PTC Therapeutics, Ovid Therapeutics and Teva.
Key figures
- Drug Name
- Privosegtor
- Phase Of Trial
- registrational (PIONEER program)
- Publications authored
- over 135
- Trials conducted at marburg
- more than 75 randomized controlled trials
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.